Creating a medicinal psilocybin treatment fund and a pilot program to study the effects of medicinal psilocybin treatment on patients with post-traumatic stress syndrome at the University of Wisconsin-Madison and making an appropriation. (FE)
Impact
The introduction of AB753 can significantly alter the state’s approach to mental health treatment for veterans. By promoting research into psilocybin therapy, this bill could pave the way for legal medicinal use of psychedelics in Wisconsin. Furthermore, as the University of Wisconsin-Madison collaborates with its Transdisciplinary Center for Research in Psychoactive Substances, the study results could potentially influence legislation regarding mental health treatments statewide and contribute to discussions around veteran care and innovative therapies.
Summary
Assembly Bill 753 establishes a pilot program to examine the effects of medicinal psilocybin treatment on veterans suffering from treatment-resistant post-traumatic stress syndrome (PTSD). The pilot program will be managed by the University of Wisconsin-Madison and is positioned to create a trust fund dedicated to providing resources for this initiative. Eligible participants must be veterans aged 21 and older, while law enforcement officers are excluded from participation. The therapy provided will follow regulatory pathways approved by the FDA, ensuring compliance with federal requirements.
Contention
Notable points of contention surrounding AB753 focus on the regulatory and societal implications of introducing psilocybin therapy. Critics may express concerns about safety, ethical considerations, and the long-term societal effects of legalizing psilocybin treatments. Additionally, there may be debates regarding funding allocations from general state revenues and the management of the newly created medicinal psilocybin treatment fund, emphasizing the need for transparency and accountability in the fund's expenditures.
Creating a medicinal psilocybin treatment fund and a pilot program to study the effects of medicinal psilocybin treatment on patients with post-traumatic stress syndrome at the University of Wisconsin-Madison and making an appropriation. (FE)
Requesting The Department Of Health To Convene A Medicinal Psilocybin And Psilocin Working Group To Examine The Medicinal And Therapeutic Effects Of Psilocybin And Psilocin And Develop A Long-term Strategic Plan To Ensure The Availability Of Medicinal Psilocybin And Psilocin Or Psilocybin-based And Psilocin-based Products That Are Safe, Accessible, And Affordable For Eligible Adult Patients.
Requesting The Department Of Health To Convene A Medicinal Psilocybin And Psilocin Working Group To Examine The Medicinal And Therapeutic Effects Of Psilocybin And Psilocin And Develop A Long-term Strategic Plan To Ensure The Availability Of Medicinal Psilocybin And Psilocin Or Psilocybin-based And Psilocin-based Products That Are Safe, Accessible, And Affordable For Eligible Adult Patients.
Requesting The Department Of Health To Convene A Medicinal Psilocybin And Psilocin Working Group To Examine The Medicinal And Therapeutic Effects Of Psilocybin And Psilocin And Develop A Long-term Strategic Plan To Ensure The Availability Of Medicinal Psilocybin And Psilocin Or Psilocybin-based And Psilocin-based Products That Are Safe, Accessible, And Affordable For Eligible Adult Patients.
Requesting The Department Of Health To Convene A Therapeutic Psilocybin Working Group To Examine The Medicinal And Therapeutic Effects Of Psilocybin And Develop A Long-term Strategic Plan, Should Food And Drug Administration Approval For Medical Use Be Obtained, To Enable The Availability Of Therapeutic Psilocybin Or Psilocybin-based Products That Are Safe, Accessible, And Affordable For Adults Twenty-one Years Of Age Or Older.
Requesting The Department Of Health To Convene A Therapeutic Psilocybin Working Group To Examine The Medicinal And Therapeutic Effects Of Psilocybin And Develop A Longterm Strategic Plan, Should Food And Drug Administration Approval For Medical Use Be Obtained, To Enable The Availability Of Therapeutic Psilocybin Or Psilocybin-based Products That Are Safe, Accessible, And Affordable For Adults Twenty-one Years Of Age Or Older.